Literature DB >> 31646272

Heart failure: an underestimated therapeutic target in diabetes.

Nikolaus Marx1.   

Abstract

Heart failure (HF) is a frequent finding in patients with diabetes and is associated with an impaired prognosis with respect to the need for hospitalization as well as mortality. The following article presents an overview of the incidence and prognosis of HF in patients with type 2 diabetes and discusses the effects of various antidiabetic drugs on HF.
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Keywords:  diabetes; heart failure; therapy

Year:  2018        PMID： 31646272      PMCID： PMC6739885          DOI： 10.1097/XCE.0000000000000138

Source DB:  PubMed          Journal:  Cardiovasc Endocrinol Metab        ISSN： 2574-0954


  14 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Prevalence and prognostic implications of pre-diabetic state in patients with heart failure.

Authors:  Yuya Matsue; Makoto Suzuki; Rena Nakamura; Masami Abe; Maki Ono; Seigo Yoshida; Mie Seya; Ryota Iwatsuka; Akira Mizukami; Masahiko Setoguchi; Wataru Nagahori; Masakazu Ohno; Akihiko Matsumura; Yuji Hashimoto
Journal:  Circ J       Date:  2011-10-19       Impact factor: 2.993

3.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

4.  New type of cardiomyopathy associated with diabetic glomerulosclerosis.

Authors:  S Rubler; J Dlugash; Y Z Yuceoglu; T Kumral; A W Branwood; A Grishman
Journal:  Am J Cardiol       Date:  1972-11-08       Impact factor: 2.778

5.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

6.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 7.  Diabetic cardiomyopathy: myth or reality?

Authors:  Laura Ernande; Geneviève Derumeaux
Journal:  Arch Cardiovasc Dis       Date:  2012-03-09       Impact factor: 2.340

8.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

9.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.

Authors:  Michael R MacDonald; Mark C Petrie; Fumi Varyani; Jan Ostergren; Eric L Michelson; James B Young; Scott D Solomon; Christopher B Granger; Karl Swedberg; Salim Yusuf; Marc A Pfeffer; John J V McMurray
Journal:  Eur Heart J       Date:  2008-04-14       Impact factor: 29.983

10.  Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure.

Authors:  Ida Gustafsson; Bente Brendorp; Marie Seibaek; Hans Burchardt; Per Hildebrandt; Lars Køber; Christian Torp-Pedersen
Journal:  J Am Coll Cardiol       Date:  2004-03-03       Impact factor: 24.094
View more
  1 in total

Review 1.  Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatment.

Authors:  Atsushi Tanaka; Koichi Node
Journal:  Diabetol Int       Date:  2020-06-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.